Linked from

The 13 pages that link to Tardive dyskinesia, each with the reason it gives.

• AntipsychoticRelated: Long-term dopamine receptor blockade can cause this potentially persistent adverse effect.

• Dopamine D2 receptorRelated: Long-term D2-blocking treatment is a major risk factor for this movement disorder.

• MetoclopramideRelated: Long-term metoclopramide exposure can cause this potentially persistent adverse effect.

• Extrapyramidal symptomsBroader topic: It can emerge after prolonged exposure and may persist after the causative drug is reduced.

• PsychopharmacologyBroader topic: This serious potential complication influences antipsychotic selection and monitoring.

• AkathisiaCompared with: Both can follow antipsychotic treatment, but tardive dyskinesia involves involuntary movements without akathisia's characteristic inner restlessness.

• Vesicular monoamine transporter 2Related: VMAT2 inhibitors are established treatments for this disorder.

• RisperidoneRelated: Long-term risperidone use carries a risk of this potentially persistent adverse effect.

• ChoreaRelated: Its choreiform movements can resemble chorea, but the medication history and movement pattern help distinguish them.

• HaloperidolBroader topic: Long-term haloperidol treatment can cause this potentially persistent complication.

• OlanzapineRelated: Like other antipsychotics, olanzapine carries a risk of this potentially persistent complication.

• QuetiapineRelated: Its risk is lower than with many older antipsychotics but remains relevant during long-term use.

• FluphenazineRelated: Long-term fluphenazine treatment can carry this risk.